ALPINE, Utah -- American Biotech Labs recently completed a series of tests at a level three laboratory using its newly approved medical disinfectant ASAP-AGX-32. The product was tested against a concentration of 81,000,000 Y. pestis bacteria per milliliter. It killed all of them in less than two minutes.
Y. pestis is a bacterium that causes Bubonic Plague, also known as the black death. It killed one third of the population of Europe in the 14th century, and even today can kill 60 percent of untreated victims in three to five days. While there have been sporadic outbreaks in the United States, a more serious concern is the potential for weaponized Plague.
Said Keith Moeller, vice president of American Biotech Labs, "The ASAP-AGX-32 product has already been approved by the Environmental Protection Agency (EPA) for use against gram negative bacteria and Y. pestis is a gram negative bacterium. We wanted to test the limits of the product's capability, and we are delighted with the results. A normal in vitro (test tube) bacterial test uses a load of 500,000 bacteria per milliliter. The level of plague causing bacteria in our sample was 160 times that normal amount. The ASAP-AGX-32 disinfectant killed the bacteria in less than two minutes."
The ASAP-AGX-32 (EPA registration No. 73499-2) is unique in that it has no color or odor. Unlike other disinfectants, the ASAP ASAP-AGX-32 can be used or sprayed around both adults and children with no toxic effect. The product is not known to irritate the skin, eyes, nose, or lungs. To date, this product has killed every strain of every bacterium on which it has been tested. It has received EPA approval for use against the most deadly bacteria, including gram negative, gram positive and even nosocomial or hospital acquired (superbug) pathogens. The product has been approved for use as a broad spectrum, general use surface disinfectant in homes, hospitals, and medical settings.
Source: Clifton Mining Company
Genomic Surveillance A New Frontier in Health Care Outbreak Detection
November 27th 2024According to new research, genomic surveillance is transforming health care-associated infection detection by identifying outbreaks earlier, enabling faster interventions, improving patient outcomes, and reducing costs.
Point-of-Care Engagement in Long-Term Care Decreasing Infections
November 26th 2024Get Well’s digital patient engagement platform decreases hospital-acquired infection rates by 31%, improves patient education, and fosters involvement in personalized care plans through real-time interaction tools.
Comprehensive Strategies in Wound Care: Insights From Madhavi Ponnapalli, MD
November 22nd 2024Madhavi Ponnapalli, MD, discusses effective wound care strategies, including debridement techniques, offloading modalities, appropriate dressing selection, compression therapy, and nutritional needs for optimal healing outcomes.
The Leapfrog Group and the Positive Effect on Hospital Hand Hygiene
November 21st 2024The Leapfrog Group enhances hospital safety by publicizing hand hygiene performance, improving patient safety outcomes, and significantly reducing health care-associated infections through transparent standards and monitoring initiatives.